Author:
Malik Adnan,Inayat Faisal,Malik Muhammad Imran,Afzal Muhammad,Azrak Muhammad F
Reference17 articles.
1. Severe spruelike enteropathy associated with olmesartan;Rubio-Tapia A;Mayo Clin Proc,2012
2. Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review;Kamal A;Gastroenterol Rep (Oxf),2019
3. FDA Drug Safety Communication. FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. (2013). Accessed: February 21, 2020: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-inclu....
4. Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution following discontinuation of drug;Nielsen JA;World J Gastroenterol,2013
5. Drug-induced Sprue-like intestinal disease;Freeman HJ;Int J Celiac Dis,2014
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献